A comparative analysis of serum and serum-free media for generation of clinical grade DCs

Chiara Napoletano, Dora Pinto, Filippo Bellati, Federica Taurino, Hassan Rahimi, Federica Tomao, Pierluigi Benedetti Panici, Aurelia Rughetti, Luigi Frati, Marianna Nuti

Research output: Contribution to journalArticle

Abstract

Dendritic cells (DCs) are the most potent antigen presenting cells and are therefore widely used in cancer immunotherapy. An optimal method for the generation of DCs for clinical use remains to be established. The aim of the study was to find a serum-free media (SFM) able to generate reproducible and functional cultures of DCs for clinical studies. We characterized immature and mature DCs cultured in SFM, CellGro DC and X-VIVO15, and serum media (SM), RPMI 1640+5% human serum or autologous serum. The expression of HLA-DR, CD86, CD83 was higher in SM-cultured DCs (SM-DCs) than SFM-derived DCs (SFM-DCs). Between SFM-DCs, CellGro-cultured DCs (CellGro-DCs) showed a higher expression and an improved up-regulation capacity of all molecules as compared with X-VIVO15-derived DCs (X-VIVO15-DCs). CellGro-DCs and SM-DCs showed a similar mannose receptor expression and related endocytic capacity tested by fluorescein isothiocyanate-dextran uptake. In contrast X-VIVO15-DCs expressed low levels of mannose receptor and were unable to endocyte fluorescein isothiocyanate- dextran. DCs cultured in all conditions stimulated a mix lymphocyte reaction, but CellGro-DCs and SM-DCs induced a more potent T-cell proliferation compared with X-VIVO15-DCs. Cytokine analysis showed that after maturation, all DC cultures produced IL-12p70 and IL-10 except for X-VIVO15-DCs which only produced the latter cytokine. SM-DCs and SFM-DCs induced a TH1 polarization in allogeneic naive T cells. In conclusion, a comparative analysis of DC performance generated in different conditions allows us to determine CellGro DC as the optimal medium for the generation of clinical grade DCs.

Original languageEnglish
Pages (from-to)567-576
Number of pages10
JournalJournal of Immunotherapy
Volume30
Issue number5
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Serum-Free Culture Media
Dendritic Cells
Serum
Cultured Cells
Cytokines
T-Lymphocytes

Keywords

  • Dendritic cells
  • Immunotherapy
  • Serum-free culture

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Napoletano, C., Pinto, D., Bellati, F., Taurino, F., Rahimi, H., Tomao, F., ... Nuti, M. (2007). A comparative analysis of serum and serum-free media for generation of clinical grade DCs. Journal of Immunotherapy, 30(5), 567-576. https://doi.org/10.1097/CJI.0b013e318046f396

A comparative analysis of serum and serum-free media for generation of clinical grade DCs. / Napoletano, Chiara; Pinto, Dora; Bellati, Filippo; Taurino, Federica; Rahimi, Hassan; Tomao, Federica; Panici, Pierluigi Benedetti; Rughetti, Aurelia; Frati, Luigi; Nuti, Marianna.

In: Journal of Immunotherapy, Vol. 30, No. 5, 07.2007, p. 567-576.

Research output: Contribution to journalArticle

Napoletano, C, Pinto, D, Bellati, F, Taurino, F, Rahimi, H, Tomao, F, Panici, PB, Rughetti, A, Frati, L & Nuti, M 2007, 'A comparative analysis of serum and serum-free media for generation of clinical grade DCs', Journal of Immunotherapy, vol. 30, no. 5, pp. 567-576. https://doi.org/10.1097/CJI.0b013e318046f396
Napoletano, Chiara ; Pinto, Dora ; Bellati, Filippo ; Taurino, Federica ; Rahimi, Hassan ; Tomao, Federica ; Panici, Pierluigi Benedetti ; Rughetti, Aurelia ; Frati, Luigi ; Nuti, Marianna. / A comparative analysis of serum and serum-free media for generation of clinical grade DCs. In: Journal of Immunotherapy. 2007 ; Vol. 30, No. 5. pp. 567-576.
@article{f20e93f00f6c477c9690c5f739adb6ad,
title = "A comparative analysis of serum and serum-free media for generation of clinical grade DCs",
abstract = "Dendritic cells (DCs) are the most potent antigen presenting cells and are therefore widely used in cancer immunotherapy. An optimal method for the generation of DCs for clinical use remains to be established. The aim of the study was to find a serum-free media (SFM) able to generate reproducible and functional cultures of DCs for clinical studies. We characterized immature and mature DCs cultured in SFM, CellGro DC and X-VIVO15, and serum media (SM), RPMI 1640+5{\%} human serum or autologous serum. The expression of HLA-DR, CD86, CD83 was higher in SM-cultured DCs (SM-DCs) than SFM-derived DCs (SFM-DCs). Between SFM-DCs, CellGro-cultured DCs (CellGro-DCs) showed a higher expression and an improved up-regulation capacity of all molecules as compared with X-VIVO15-derived DCs (X-VIVO15-DCs). CellGro-DCs and SM-DCs showed a similar mannose receptor expression and related endocytic capacity tested by fluorescein isothiocyanate-dextran uptake. In contrast X-VIVO15-DCs expressed low levels of mannose receptor and were unable to endocyte fluorescein isothiocyanate- dextran. DCs cultured in all conditions stimulated a mix lymphocyte reaction, but CellGro-DCs and SM-DCs induced a more potent T-cell proliferation compared with X-VIVO15-DCs. Cytokine analysis showed that after maturation, all DC cultures produced IL-12p70 and IL-10 except for X-VIVO15-DCs which only produced the latter cytokine. SM-DCs and SFM-DCs induced a TH1 polarization in allogeneic naive T cells. In conclusion, a comparative analysis of DC performance generated in different conditions allows us to determine CellGro DC as the optimal medium for the generation of clinical grade DCs.",
keywords = "Dendritic cells, Immunotherapy, Serum-free culture",
author = "Chiara Napoletano and Dora Pinto and Filippo Bellati and Federica Taurino and Hassan Rahimi and Federica Tomao and Panici, {Pierluigi Benedetti} and Aurelia Rughetti and Luigi Frati and Marianna Nuti",
year = "2007",
month = "7",
doi = "10.1097/CJI.0b013e318046f396",
language = "English",
volume = "30",
pages = "567--576",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A comparative analysis of serum and serum-free media for generation of clinical grade DCs

AU - Napoletano, Chiara

AU - Pinto, Dora

AU - Bellati, Filippo

AU - Taurino, Federica

AU - Rahimi, Hassan

AU - Tomao, Federica

AU - Panici, Pierluigi Benedetti

AU - Rughetti, Aurelia

AU - Frati, Luigi

AU - Nuti, Marianna

PY - 2007/7

Y1 - 2007/7

N2 - Dendritic cells (DCs) are the most potent antigen presenting cells and are therefore widely used in cancer immunotherapy. An optimal method for the generation of DCs for clinical use remains to be established. The aim of the study was to find a serum-free media (SFM) able to generate reproducible and functional cultures of DCs for clinical studies. We characterized immature and mature DCs cultured in SFM, CellGro DC and X-VIVO15, and serum media (SM), RPMI 1640+5% human serum or autologous serum. The expression of HLA-DR, CD86, CD83 was higher in SM-cultured DCs (SM-DCs) than SFM-derived DCs (SFM-DCs). Between SFM-DCs, CellGro-cultured DCs (CellGro-DCs) showed a higher expression and an improved up-regulation capacity of all molecules as compared with X-VIVO15-derived DCs (X-VIVO15-DCs). CellGro-DCs and SM-DCs showed a similar mannose receptor expression and related endocytic capacity tested by fluorescein isothiocyanate-dextran uptake. In contrast X-VIVO15-DCs expressed low levels of mannose receptor and were unable to endocyte fluorescein isothiocyanate- dextran. DCs cultured in all conditions stimulated a mix lymphocyte reaction, but CellGro-DCs and SM-DCs induced a more potent T-cell proliferation compared with X-VIVO15-DCs. Cytokine analysis showed that after maturation, all DC cultures produced IL-12p70 and IL-10 except for X-VIVO15-DCs which only produced the latter cytokine. SM-DCs and SFM-DCs induced a TH1 polarization in allogeneic naive T cells. In conclusion, a comparative analysis of DC performance generated in different conditions allows us to determine CellGro DC as the optimal medium for the generation of clinical grade DCs.

AB - Dendritic cells (DCs) are the most potent antigen presenting cells and are therefore widely used in cancer immunotherapy. An optimal method for the generation of DCs for clinical use remains to be established. The aim of the study was to find a serum-free media (SFM) able to generate reproducible and functional cultures of DCs for clinical studies. We characterized immature and mature DCs cultured in SFM, CellGro DC and X-VIVO15, and serum media (SM), RPMI 1640+5% human serum or autologous serum. The expression of HLA-DR, CD86, CD83 was higher in SM-cultured DCs (SM-DCs) than SFM-derived DCs (SFM-DCs). Between SFM-DCs, CellGro-cultured DCs (CellGro-DCs) showed a higher expression and an improved up-regulation capacity of all molecules as compared with X-VIVO15-derived DCs (X-VIVO15-DCs). CellGro-DCs and SM-DCs showed a similar mannose receptor expression and related endocytic capacity tested by fluorescein isothiocyanate-dextran uptake. In contrast X-VIVO15-DCs expressed low levels of mannose receptor and were unable to endocyte fluorescein isothiocyanate- dextran. DCs cultured in all conditions stimulated a mix lymphocyte reaction, but CellGro-DCs and SM-DCs induced a more potent T-cell proliferation compared with X-VIVO15-DCs. Cytokine analysis showed that after maturation, all DC cultures produced IL-12p70 and IL-10 except for X-VIVO15-DCs which only produced the latter cytokine. SM-DCs and SFM-DCs induced a TH1 polarization in allogeneic naive T cells. In conclusion, a comparative analysis of DC performance generated in different conditions allows us to determine CellGro DC as the optimal medium for the generation of clinical grade DCs.

KW - Dendritic cells

KW - Immunotherapy

KW - Serum-free culture

UR - http://www.scopus.com/inward/record.url?scp=34250873405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250873405&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e318046f396

DO - 10.1097/CJI.0b013e318046f396

M3 - Article

C2 - 17589298

AN - SCOPUS:34250873405

VL - 30

SP - 567

EP - 576

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 5

ER -